Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma - PubMed (original) (raw)

Case Reports

. 2013 Nov 10;31(32):e439-42.

doi: 10.1200/JCO.2012.47.7521. Epub 2013 Sep 16.

Marit M van Buuren, Daisy Philips, Arno Velds, Mireille Toebes, Bianca Heemskerk, Laura J A van Dijk, Sam Behjati, Henk Hilkmann, Dris El Atmioui, Marja Nieuwland, Michael R Stratton, Ron M Kerkhoven, Can Kesmir, John B Haanen, Pia Kvistborg, Ton N Schumacher

Affiliations

• PMID: 24043743
• PMCID: PMC3836220
• DOI: 10.1200/JCO.2012.47.7521

Case Reports

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

Nienke van Rooij et al. J Clin Oncol. 2013.

No abstract available

PubMed Disclaimer

Figures

Figure 1

Patient characteristics

Figure 2

Overview of screening procedure

Figure 3

Functional characterization of ATRS>L specific T cells

Comment in

• Tumor antigenicity revealed.
  Savage PA. Savage PA. Trends Immunol. 2014 Feb;35(2):47-8. doi: 10.1016/j.it.2014.01.001. Epub 2014 Jan 15. Trends Immunol. 2014. PMID: 24439426 Free PMC article.

Similar articles

• Genetic basis for clinical response to CTLA-4 blockade in melanoma.
  Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA. Snyder A, et al. N Engl J Med. 2014 Dec 4;371(23):2189-2199. doi: 10.1056/NEJMoa1406498. Epub 2014 Nov 19. N Engl J Med. 2014. PMID: 25409260 Free PMC article.
• An immune-active tumor microenvironment favors clinical response to ipilimumab.
  Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V. Ji RR, et al. Cancer Immunol Immunother. 2012 Jul;61(7):1019-31. doi: 10.1007/s00262-011-1172-6. Epub 2011 Dec 7. Cancer Immunol Immunother. 2012. PMID: 22146893 Free PMC article. Clinical Trial.
• Probing T-cell Infiltration in Tumors.
  [No authors listed] [No authors listed] Cancer Discov. 2017 Jan;7(1):5-6. doi: 10.1158/2159-8290.CD-NB2016-154. Epub 2016 Dec 7. Cancer Discov. 2017. PMID: 27927681
• Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
  Graziani G, Tentori L, Navarra P. Graziani G, et al. Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Pharmacol Res. 2012. PMID: 21930211 Review.
• Profile of ipilimumab and its role in the treatment of metastatic melanoma.
  Patel SP, Woodman SE. Patel SP, et al. Drug Des Devel Ther. 2011;5:489-95. doi: 10.2147/DDDT.S10945. Epub 2011 Dec 16. Drug Des Devel Ther. 2011. PMID: 22267918 Free PMC article. Review.

Cited by

• Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.
  Sun Y, Yin Z, Li S, Wu L, Zhang Y, Zhao Y, Gomes Dos Santos IL, Subudhi S, Lei P, Muzikansky A, Yuan Z, Rueda BR, Jain RK, Xu L. Sun Y, et al. Br J Cancer. 2024 Nov;131(10):1683-1693. doi: 10.1038/s41416-024-02863-9. Epub 2024 Oct 5. Br J Cancer. 2024. PMID: 39369055
• Engineered T cells for Colorectal Cancer.
  Rus Bakarurraini NAA, Kamarudin AA, Jamal R, Abu N. Rus Bakarurraini NAA, et al. Immunotherapy. 2024;16(14-15):987-998. doi: 10.1080/1750743X.2024.2391733. Epub 2024 Sep 4. Immunotherapy. 2024. PMID: 39229803 Review.
• Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study.
  Martin-Liberal J, Garralda E, García-Donas J, Soto-Castillo JJ, Mussetti A, Codony C, Martin-Lluesma S, Muñoz S, Galvao V, Lostes J, Rotxes M, Prat-Vidal C, Palomero J, Muñoz A, Moreno R, García Del Muro X, Sureda A, Alemany R, Gros A, Piulats JM. Martin-Liberal J, et al. Future Oncol. 2024;20(32):2437-2445. doi: 10.1080/14796694.2024.2385287. Epub 2024 Aug 12. Future Oncol. 2024. PMID: 39129675 Clinical Trial.
• Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens.
  Hao Q, Long Y, Yang Y, Deng Y, Ding Z, Yang L, Shu Y, Xu H. Hao Q, et al. Vaccines (Basel). 2024 Jun 27;12(7):717. doi: 10.3390/vaccines12070717. Vaccines (Basel). 2024. PMID: 39066355 Free PMC article. Review.
• FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
  Hackenbruch C, Bauer J, Heitmann JS, Maringer Y, Nelde A, Denk M, Zieschang L, Kammer C, Federmann B, Jung S, Martus P, Malek NP, Nikolaou K, Salih HR, Bitzer M, Walz JS. Hackenbruch C, et al. Front Oncol. 2024 Mar 28;14:1367450. doi: 10.3389/fonc.2024.1367450. eCollection 2024. Front Oncol. 2024. PMID: 38606105 Free PMC article.

References

1. 1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipili-mumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723. - PMC - PubMed
2. 1. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465. - PMC - PubMed
3. 1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454. - PMC - PubMed
4. 1. Heemskerk B, Kvistborg P, Schumacher TN. The cancer antigenome. EMBO J. 2013;32:194–203. - PMC - PubMed
5. 1. Kvistborg P, Shu CJ, Heemskerk B, et al. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients. Oncoimmu-nology. 2012;1:409–418. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information